BioNTech plans to return €2bn to shareholders through share buybacks and a special dividend following the commercial success of its Covid-19 vaccine, the company said on Wednesday.
BioNTech周三宣布拟通过股票回购和特别股息向股东返还20亿欧元，此前该公司的新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）疫苗取得商业成功。
您已阅读12%（259字），剩余88%（1963字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。